Brian Williams

List of Publications by Year
in descending order

35 papers	6,891 citations	236612 25 h-index	377514 34 g-index
36 all docs	36 docs citations	36 times ranked	8152 citing authors

#	Article	IF	Citations
1	Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, The, 2009, 373, 48-57.	6.3	1,720
2	Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infectious Diseases, The, 2002, 2, 25-32.	4.6	735
3	The Population Dynamics and Control of Tuberculosis. Science, 2010, 328, 856-861.	6.0	559
4	Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet, The, 1998, 352, 1886-1891.	6.3	393
5	A consistent log-linear relationship between tuberculosis incidence and body mass index. International Journal of Epidemiology, 2010, 39, 149-155.	0.9	323
6	The Potential Impact of Male Circumcision on HIV in Sub-Saharan Africa. PLoS Medicine, 2006, 3, e262.	3.9	290
7	Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis. Science, 2002, 295, 2042-2046.	6.0	289
8	Highly active antiretroviral treatment for the prevention of HIV transmission. Journal of the International AIDS Society, 2010, 13, 1-1.	1.2	285
9	Trends in tuberculosis incidence and their determinants in 134 countries. Bulletin of the World Health Organization, 2009, 87, 683-691.	1.5	282
10	Tuberculosis control in the era of HIV. Nature Reviews Immunology, 2005, 5, 819-826.	10.6	216
11	Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS. Science, 2003, 301, 1535-1537.	6.0	214
12	Criteria for the control of drug-resistant tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8180-8185.	3.3	209
13	Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infectious Diseases, The, 2003, 3, 349-358.	4.6	206
14	Diabetes and the risk of tuberculosis: a neglected threat to public health?. Chronic Illness, 2007, 3, 228-245.	0.6	181
15	Effects of Human Immunodeficiency Virus Infection on Recurrence of Tuberculosis after Rifampin-Based Treatment: An Analytical Review. Clinical Infectious Diseases, 2003, 37, 101-112.	2.9	153
16	Eliminating human tuberculosis in the twenty-first century. Journal of the Royal Society Interface, 2008, 5, 653-662.	1.5	135
17	Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infectious Diseases, The, 2006, 6, 483-495.	4.6	132
18	Antiretroviral therapy for tuberculosis control in nine African countries. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19485-19489.	3.3	89

#	Article	IF	Citations
19	HIV Treatment as Prevention: Debate and Commentary—Will Early Infection Compromise Treatment-as-Prevention Strategies?. PLoS Medicine, 2012, 9, e1001232.	3.9	88
20	Epidemiological metrics and benchmarks for a transition in the HIV epidemic. PLoS Medicine, 2018, 15, e1002678.	3.9	59
21	Nutrition, Diabetes and Tuberculosis in the Epidemiological Transition. PLoS ONE, 2011, 6, e21161.	1.1	57
22	Clinical Prognostic Value of RNA Viral Load and CD4 Cell Counts during Untreated HIV-1 Infection—A Quantitative Review. PLoS ONE, 2009, 4, e5950.	1.1	55
23	What is the limit to case detection under the DOTS strategy for tuberculosis control?. Tuberculosis, 2003, 83, 35-43.	0.8	44
24	Infectious disease persistence when transmission varies seasonally. Mathematical Biosciences, 1997, 145, 77-88.	0.9	34
25	Measles vaccination policy. Epidemiology and Infection, 1995, 115, 603-621.	1.0	31
26	The scale and dynamics of COVID-19 epidemics across Europe. Royal Society Open Science, 2020, 7, 201726.	1.1	21
27	Universal voluntary HIV testing and immediate antiretroviral therapy – Authors' reply. Lancet, The, 2009, 373, 1080-1081.	6.3	19
28	Slow Elimination of Multidrug-Resistant Tuberculosis. Science Translational Medicine, 2009, 1, 3ra8.	5.8	17
29	Modelling challenges in context: Lessons from malaria, HIV, and tuberculosis. Epidemics, 2015, 10, 102-107.	1.5	16
30	New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bulletin of the World Health Organization, 2009, 87, 186-192.	1.5	14
31	Incongruent HIV and tuberculosis co-dynamics in Kenya: Interacting epidemics monitor each other. Epidemics, 2009, 1, 14-20.	1.5	10
32	Mass treatment to eliminate tuberculosis from an island population. International Journal of Tuberculosis and Lung Disease, 2014, 18, 899-904.	0.6	8
33	Modelling local and global effects on the risk of contracting Tuberculosis using stochastic Markov-chain models. Mathematical Biosciences, 2009, 218, 98-104.	0.9	3
34	A signature for biological heterogeneity in susceptibility to HIV infection?. Infectious Disease Modelling, 2018, 3, 139-144.	1.2	3
35	Reply to Lawn and Wood. Journal of Infectious Diseases, 2007, 195, 1079-1079.	1.9	0